financetom
Business
financetom
/
Business
/
Nvidia's New Chips Likely to Help Extend AI Value Chain Dominance, Analysts Say
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nvidia's New Chips Likely to Help Extend AI Value Chain Dominance, Analysts Say
Mar 19, 2024 8:18 AM

10:58 AM EDT, 03/19/2024 (MT Newswires) -- Nvidia's ( NVDA ) new Blackwell computing platform, along with a series of artificial intelligence chips, should give the semiconductor maker a competitive edge in the AI accelerator market, multiple analysts said on Tuesday.

The offerings, announced during its developer's conference in San Jose, included the B100, B200, and GB200 chips. The company's stock has rallied 74% so far this year, and is up nearly 230% over the last 12 months.

Nvidia ( NVDA ) "continues to lift the performance bar, a result that should help sustain (its) leadership position in the AI accelerator market," Wedbush analyst Matt Bryson wrote in a note. Its efforts with systems architecture could be tough for competitors to replicate, suggesting that Nvidia ( NVDA ) is "uniquely positioned" against its peers, he said.

The B100 chip is expected to double training performance compared with the Hopper graphics processing unit, while the B200 offers four-times the training performance, according to Wedbush. The GB200 NVL72 delivers 30-times faster trillion-parameter large language model, or LLM, inference, Nvidia's ( NVDA ) website showed.

Amazon.com's ( AMZN ) Amazon Web Services, Dell Technologies ( DELL ) , Alphabet (GOOG, GOOGL) unit Google ( GOOG ), Meta Platforms ( META ) , Microsoft ( MSFT ) , OpenAI, Oracle (ORCL) and Tesla (TSLA) are among companies expected to adopt Blackwell, Nvidia ( NVDA ) said Monday.

"Competing with this roadmap, as a direct merchant competitor or a custom silicon provider, is going to be very difficult, particularly given Nvidia's ( NVDA ) shift to an annual cadence," Morgan Stanley said.

At the event on Monday, Nvidia ( NVDA ) also highlighted progress on creating an AI software ecosystem for the enterprise, with new microservices that enable businesses to build and run inference on customized or pretrained models, according to Morgan Stanley.

"With Blackwell, (Nvidia ( NVDA )) should not only cement its lead in LLM training, but also significantly step forward in AI inference," BofA Securities said in a note emailed Tuesday.

Price: 864.43, Change: -20.12, Percent Change: -2.27

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BTU Dixie East Project Approved
BTU Dixie East Project Approved
Oct 27, 2025
VANCOUVER, BC / ACCESS Newswire ( ACCS ) / October 27, 2025 / BTU METALS CORP. ( BTUMF ) (BTU or the Company) (OTCQB:BTUMF) is pleased to announce the acquisition of the 100% interest in the newly secured Dixie East Project, a large and strategically located land package immediately east of Kinross Gold's ( KGCRF ) world-renowned Great Bear Dixie...
Organon CEO Kevin Ali to resign after probe into contraceptive sales
Organon CEO Kevin Ali to resign after probe into contraceptive sales
Oct 27, 2025
Oct 27 (Reuters) - Organon said on Monday CEO Kevin Ali will resign from his role, after an internal investigation into sales of its Nexplanon contraceptive implant to wholesalers pointed to improper practices. An audit committee found certain U.S. wholesalers were asked to purchase more Nexplanon than needed at the end of several quarters between 2022 and 2025. While the...
Johnson & Johnson Says 2-Year Data for Tremfya in Crohn's Disease Shows Durable Remission
Johnson & Johnson Says 2-Year Data for Tremfya in Crohn's Disease Shows Durable Remission
Oct 27, 2025
08:01 AM EDT, 10/27/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Monday that long-term extensions of its phase 3 studies showed that its drug, Tremfya, maintained high rates of clinical and endoscopic remission in adults with moderately to severely active Crohn's disease through two years. The drugmaker said the studies evaluated patients who received either subcutaneous or...
Intellia Therapeutics Pauses Dosing in Phase 3 Trials After Grade 4 Liver Transaminases Reported in Participant
Intellia Therapeutics Pauses Dosing in Phase 3 Trials After Grade 4 Liver Transaminases Reported in Participant
Oct 27, 2025
08:01 AM EDT, 10/27/2025 (MT Newswires) -- Intellia Therapeutics ( NTLA ) said Monday it has paused patient dosing and screening for its two phase 3 clinical trials of nex-z for patients with transthyretin amyloidosis with cardiomyopathy and polyneuropathy, respectively, after a patient was reported with Grade 4 liver transaminases and increased total bilirubin after dosage with the drug. The...
Copyright 2023-2025 - www.financetom.com All Rights Reserved